| Trial ID: | L6720 |
| Source ID: | NCT05566028
|
| Associated Drug: |
D745 Formulation I
|
| Title: |
The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: D745 formulation I|DRUG: D745 formulation II|DRUG: D745 Placebo
|
| Outcome Measures: |
Primary: Change from baseline in HbA1c, Baseline, 24 week | Secondary: Change from baseline in HbA1c, Baseline, 12 week|Change from baseline in Fasting plasma glucose, Baseline, 12 week, 24 week
|
| Sponsor/Collaborators: |
Sponsor: Chong Kun Dang Pharmaceutical
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
172
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-10-12
|
| Completion Date: |
2024-07-23
|
| Results First Posted: |
|
| Last Update Posted: |
2024-12-10
|
| Locations: |
Seoul National University Hospital, Seoul, Jongno-gu, 03080, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT05566028
|
